Graduation Date

Fall 12-19-2025

Document Type

Dissertation

Degree Name

Doctor of Philosophy (PhD)

Programs

Biochemistry & Molecular Biology

First Advisor

Mohd Wasim Nasser

Abstract

Small-cell lung cancer (SCLC) is an aggressive malignancy that is generally considered an immune desert. The therapeutic impact of immune checkpoint inhibitors in SCLC is modest and confined to a small population of patients. The immune checkpoint protein B7-H3 (also known as CD276) is highly expressed in SCLC; however, its functional contribution to SCLC remains unexplored. Here, to dissect tumor-intrinsic and immunomodulatory functions of B7-H3, we generated a novel genetically engineered mouse (GEM) model Rb1fl/fl; Trp53fl/fl; LSL-MycT58A; Cd276fl/fl (RPMC). Cd276 deletion significantly impaired primary tumor growth, metastatic dissemination, and reprogrammed the SCLC tumor microenvironment by increasing CD8+ T-cell infiltration and decreasing immunosuppressive myeloid populations. Loss of B7-H3 also improved responsiveness to combination therapy (cisplatin and anti-PD-L1) by modulating the anti-tumor immune response. Mechanistically, B7-H3 regulates NFIB through a CXCL11-CXCR7 feed-forward loop. To further evaluate translational implications, we tested a B7-H3 targeted antibody-drug conjugate m276-SL-PBD, which abrogated SCLC in the GEM model. Collectively, our findings establish B7-H3 as a key regulator of SCLC progression, metastatic competence, and immune escape, and highlight B7-H3-directed therapies as promising strategies for this recalcitrant disease.

Comments

2025 Copyright, the authors

Rights

The author holds the copyright to this work and any reuse or permissions must be obtained from the author directly.

Download

Available for download on Sunday, December 12, 2027

Share

COinS